Cancer-drug shortages in the U.S. have caused hundreds of clinical trials to be stopped or delayed, threatening progress on new treatments, a top health official told Congress Friday.

Howard Koh, assistant secretary of health for the Department of Health and Human Services, said drug shortages are "dramatically affecting clinical trials." Dr. Koh testified Friday before the House Energy and Commerce Subcommittee on Health during a hearing on drug shortages.

"The inability to obtain adequate supplies of these cancer drugs for research has resulted in promising clinical trials being suspended indefinitely and patient enrollment being abruptly halted,"

Comments

Search RSS

All rights reserved."